Table 3.
Tumor vaccination clinical trials for oral cancers
| Vaccines | Sponsor | Nationality | Estimated date of completion | Phase | Status | Identifier |
|---|---|---|---|---|---|---|
| HPV Vaccination | Oslo University Hospital | Norway | February 2017 | Completed | NCT02934724 | |
| ADXS-HPV | Andrew Sikora | United States | August 2023 | II | Active | NCT02002182 |
| Utomilumab and ISA101b | M.D. Anderson Cancer Center | United States | June 2022 | II | Active | NCT03258008 |
| HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-Beta Trap (M7824) | National Cancer Institute (NCI) | United States | October 2023 | I/II | Recruiting | NCT04432597 |
| HPV Vaccination | Regenstrief Institute, Inc | United States | June 2015 | Completed | NCT02551887 | |
| HPV Vaccination | Regenstrief Institute, Inc | United States | May 2016 | Completed | NCT02558803 | |
| HPV Vaccination | Boston Medical Center | United States | April 2019 | Completed | NCT03346915 | |
| HPV Vaccination | National Cancer Institute (NCI) | United States | July 2022 | Active | NCT00867464 | |
| Recombinant Fowl Pox Vaccine rF-CEA (6D)/TRICOM With GM-CSF | National Cancer Institute (NCI) | United States | January 2013 | I | Completed | NCT00028496 |
| TheraT® Vectors combined with chemotherapy | University of Chicago | United States | January 2026 | I/II | Not yet recruiting | NCT05108870 |
| PDS0101 + NHS-IL12 + M7824 | National Cancer Institute (NCI) | United States | January 2023 | I/II | Recruiting | NCT04287868 |
| Tumor-specific mutated Ras peptides and IL-2 or GM-CSF | National Cancer Institute (NCI) | United States | May 2007 | II | Completed | NCT00019331 |
| HPV Vaccination | National Cancer Institute (NCI) | United States | April 2015 | I | Completed | NCT00019110 |
| HPV Vaccination | University of Birmingham | United Kingdom | September 2015 | Completed | NCT01330147 | |
| Recombinant fowlpox-TRICOM | National Institute on Deafness and Other Communication Disorders (NIDCD) | United States | April 2015 | I | Completed | NCT00021424 |
| HPV16-E711-19 Nanomer | Dana-Farber Cancer Institute | United States | May 2023 | I/II | Active | NCT02865135 |
| DCs loaded with wild-type p53 peptides with T-helper peptide epitope | Robert Ferris | United States | March 2014 | I | Completed | NCT00404339 |
CEA Carcino-embryonic antigen; GM-CSF granulocyte/macrophage colony-stimulating factor; HPV human papillomavirus; IL-12 interleukin-12; PD-L1 programmed cell death-ligand 1; Ras Rat sarcoma; TGF-β transforming growth factor-β; TRICOM Triad of costimulatory molecules